

- Rheumatic fever (*Cont.*):
 clinical features of, 129t, 2150
 chorea, 2151–2152, 2153
 erythema marginatum, 129t, 134, 356, 2152
 fever, 2152
 joint involvement, 837, 2151
 nodules, 364, 2152
 diagnosis of, 2151t, 2152, 2152t, 2153t
 epidemiology of, 2149, 2150f
 etiology of, 129t
 genetic considerations in, 2150
 global considerations in, 1528–1529, 2149
 group A streptococcal infection and, 233, 2152
 immunopathology of, 372e–24t, 377e–1, 2150
 pathogenesis of, 2149–2150, 2150f
 prevention of, 2153–2154, 2154t
 prognosis of, 2153
 treatment of, 2152–2153
- Rheumatic heart disease. *See* Rheumatic fever, clinical features of
- Rheumatoid arthritis (RA), **2136**
 approach to the patient, 2147–2148
 clinical features of, 2136–2139
 cardiovascular, 290e–1t, 290e–3, 2138
 aortic aneurysm, 1638
 aortitis, 1638
 AV conduction block, 1471, 1471t
 SA node dysfunction, 1467
 constitutional, 2138
 cutaneous, 76e–16f, 364, 364t, 2138
 extraarticular, 2137–2138, 2137f
 Felty's syndrome, 372e–15t
 hematologic, 372e–15t, 393, 630, 630f
 inflammation/swelling, 2137f, 2142, 2142f
 lymphoma, 2138
 neck pain, 122
 neuropathy, 2683
 oral pain, 237
 pulmonary, 1713–1714, 2138
 Raynaud's phenomenon, 1649
 Sjögren's syndrome, 2138
 T-cell large granular lymphocytic leukemia, 2138
 vasculitis, 372e–15t, 2138, 2193
 conditions associated with, 2137f, 2138–2139
 diagnosis of, 41t, 2143–2144, 2144f
 disability in, 2144
 EBV and, 2140
 environmental factors in, 2140
 epidemiology of, 2139, 2139f
 genetic considerations in, 373e–8, 373e–8t, 2139–2140
 global considerations in, 2139, 2139f, 2149
 natural history of, 2144
 pathogenesis of, 372e–22, 372e–24–25t, 372e–29t, 2141–2143, 2142f
 pathology of, 2140–2141
 prognosis of, 2144
 vs. relapsing polychondritis, 2204
 remission in, 2148, 2148t
 research progress in, 2136
 treatment of, **2144**
 approach to, 2144–2145, 2147–2148
 assistive devices, 2148
 biologic agents, 372e–30, 377e–5, 2145, 2146–2147t, 2147
 DMARDs, 2145, 2146t
 in the elderly, 2148–2149
 global considerations in, 2149
 glucocorticoids, 2145
 NSAIDs, 2145
 physical therapy, 2148
 in pregnancy, 2148
 surgery, 2148
 tofacitinib, 2147, 2147t
- Rheumatoid vasculitis, 372e–15t, 2138
- Rheumatologic diseases. *See* Musculoskeletal disorders
- Rhinitis
 allergic. *See* Allergic rhinitis
 chronic atrophic, 1032
 perennial nonallergic, 2122
 vasomotor, 2122
- Rhinophyma, 352
- Rhinorrhea, CSF, 457e–2
- Rhinoscleroma, 1032
- Rhinosinusitis. *See* Sinusitis
- Rhinovirus, 1202–1203
- Rhinovirus infections, 145e–4, 225–226, 923, 1202t, **1203**
- Rhinovirus vaccine, 1203
- Rhizobium radiobacter*, 183e–2t, 183e–3
- Rhizopus* spp., 1350, 1351f. *See also* Mucormycosis
- Rhodococcus* spp. infections, 924, 981, 1254
- Rho kinase, 324, 325f
- Rhonchi, 1662
- Ribavirin
 action of, 215e–6
 for adenovirus, 1208
 adverse effects of, 215e–6, 381, 897, 2042–2043
 for chronic HCV infection, 215e–4t, 215e–6, 215e–10, 927, 2041–2042
 drug interactions of, 2030
 genetic variations in response to, 39t
 for HRSV infection, 215e–2t, 215e–6
 for influenza, 1214
 for parainfluenza virus infection, 1208
 for viral encephalitis, 897
 for viral hemorrhagic fevers, 215e–6, 261e–5t, 261e–8, 783, 1320
- Riboflavin (vitamin B₂), **96e–3**
 deficiency of, 96e–1t, 96e–4, 463t
 functions of, 96e–2f, 96e–3–4
 parenteral requirement for, 98e–5t
 recommended intake of, 95e–2t
 reference range for, 2766t
 structure of, 96e–2f
 supplements, adverse effects of, 216
- Rice water stool, 1063, 1063f
- Rickets
 clinical features of, 96e–1t
 diagnosis of, 2465–2466
 hereditary vitamin D–resistant, 2465
 in hypophosphatasia, 426e–5
 hypophosphatemic, 332e–7t, 2458
 pathogenesis of, 96e–1t, 2465
 vitamin D–dependent type I (pseudovitamin D–deficiency), 2465, 2485
 vitamin D–dependent type II, 2485
- Rickettsia africana*, 1157
- Rickettsia akari*. *See* Rickettsialpox
- Rickettsia australis*, 128t, 1157
- Rickettsia conorii*, 782. *See also* Mediterranean spotted fever
- Rickettsia felis*, 1158
- Rickettsia honei*, 1157
- Rickettsia japonica*, 1157
- Rickettsial diseases, **1154**
 clinical features of, 127, 128t, 1154, 1155t, 2193
 diagnosis of, 150e–8
 ehrlichioses, 1159–1160, 1159f
 endemic typhus. *See* Endemic (murine) typhus
 epidemic typhus. *See* Epidemic (louse-borne) typhus
 epidemiology of, 1154, 1155t
 etiology of, 1154, 1155t
 flea-borne spotted fever, 1158
 global considerations in, 782
 human granulocytic anaplasmosis, 1152, 1159f, 1160–1161
 Mediterranean spotted (boutonneuse) fever, 128t, 782, 1157
 Q fever. *See* Q fever
 rickettsialpox. *See* Rickettsialpox
 Rocky Mountain spotted fever. *See* Rocky Mountain spotted fever (RMSF)
 scrub typhus. *See* Scrub typhus
 tick-borne spotted fevers, 1157
 in travelers, 802t
- Rickettsialpox
 clinical features of, 132t, 1155t, 1157–1158
 diagnosis of, 1158
 epidemiology of, 132t, 1155t, 1157
 etiology of, 132t
- rash in
 evolution of, 132t, 829, 1157–1158, 1157f, 1158f
 papules and plaques, 25e–9f, 132t, 134–135, 362
 transmission of, 1155t
 treatment of, 1158
 vs. varicella, 135, 1185
- Rickettsia prowazekii*, 782, 1154. *See also* Epidemic (louse-borne) typhus
- Rickettsia rickettsii*, 782. *See also* Rocky Mountain spotted fever (RMSF)
- Rickettsia sibirica*, 128t
- Rickettsia typhi*. *See* Endemic (murine) typhus
- Riedel's thyroiditis, 2299
- Rifabutin
 action of, 205e–5, 931t, 932, 936
 adverse effects of, 205e–5
 drug interactions of, 246e–3t
 for MAC infection prophylaxis in HIV infection, 1251t
 for nontuberculous mycobacterial infections, 205e–8
 pharmacology of, 205e–5
 resistance to, 931t, 934
 for TB, 205e–5
 for TB prophylaxis in HIV infection, 1251t
- Rifampin
 action of, 205e–3–4, 931t, 932f, 933
 adverse effects of, 205e–4
 allergic interstitial nephritis, 1857
 gastrointestinal, 944
 hepatotoxicity, 938t, 944
 hyperbilirubinemia, 282
 thrombocytopenia, 727t
 for anthrax, 261e–3, 261e–5t
 for asymptomatic GAS carriage, 966
 for *Brucella* infections, 194e–4
 for cat-scratch disease, 1081t
 dosage of, 205e–4
 drug interactions of, 42t, 205e–4, 939t, 1126
 antiretroviral therapy, 205e–1
 atovaquone, 246e–2t
 dapsone, 246e–4t
 quinidine, 246e–6t
 genetic variations in response to, 39, 39t
 indications for, 941t, 943–944
 for infective endocarditis, 822t, 823, 963
 for *Legionella* infections, 1020, 1020t
 for leprosy, 1126–1127, 1127t
 for meningitis, 889, 952
 metabolism of, 935
 for nontuberculous mycobacterial infections, 205e–8, 1131–1132, 1696
 for osteomyelitis, 840t, 841t, 843
 pharmacology of, 205e–4
 prophylactic
 for *H. influenzae*, 235
 for meningitis, 889, 945t
 for TB in HIV infection, 1251t
 for prosthetic joint infections, 963
 for Q fever, 1162
 for reactive arthritis, 2175
 resistance to
 detection of, 778
 mechanisms of, 931t, 934
 in mycobacteria, 205e–4, 774, 1118
 prevalence of, 941t
 for TB
 active infection, 205e–2t, 205e–3–4, 1115–1117, 1115t
 latent infection, 205e–1t, 205e–2t, 205e–3, 1121
 for tuberculous meningitis, 898
 for verruga peruana, 1081t
- Rifamycins, 931t, 933, 943
- Rifapentine
 action of, 931t, 933
 adverse effects of, 205e–5
 for latent TB, 205e–1t, 205e–5, 1121
 for leprosy, 1126
 pharmacology of, 205e–5
 for pulmonary TB, 205e–5
 resistance to, 205e–5, 931t